Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies

Blood Reviews

Volumn 25, Issue 2, 2011, Pages 91-96

  Böttcher, Sebastian ^a,b   Ritgen, Matthias ^a,b   Dreger, Peter ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allogeneic stem cell transplantation; Chronic lymphocytic leukemia; Minimal residual disease

Indexed keywords

ALEMTUZUMAB; FLUDARABINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FLOW CYTOMETRY; GEOGRAPHIC DISTRIBUTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM, RESIDUAL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79951513494     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2011.01.001     Document Type: Article

References (47)

1. Montserrat E., Moreno C., Esteve J., et al. How I Treat Refractory CLL. Blood 2006, 107:1276-1283.
2. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
3. Hallek M., Fingerle-Rowson G., Fink A., et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves overall survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:223-224.
4. Tsimberidou A.M., Keating M.J. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009, 115:2824-2836.
5. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
6. Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010.
7. Asslaber D., Pinon J.D., Seyfried I., et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010, 115:4191-4197.
8. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278-3281.
9. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979.
10. Stilgenbauer S., Zenz T., Winkler D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H trial of the GCLLSG. J Clin Oncol 2009, 27:3994-4001.
11. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1749-1755.
12. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
13. Phelps M.A., Lin T.S., Johnson A.J., et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113:2637-2645.
14. Rabinowe S.N., Soiffer R.J., Gribben J.G., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993, 82:1366-1376.
15. Michallet M., Archimbaud E., Rowlings P.A., et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukemia. Ann Intern Med 1996, 124:311-315.
16. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003, 21:2747-2753.
17. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
18. Dreger P., Döhner H., Ritgen M., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 2010, 116:2438-2447.
19. Schetelig J., van Biezen A., Brand R., et al. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective EBMT analysis. J Clin Oncol 2008, 26:5094-5100.
20. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
21. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood 2008, 111:5446-5456.
22. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
23. Böttcher S., Ritgen M., Pott C., et al. Comparative analysis of minimal residual disease detection using four color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18:1637-1645.
24. Schultze J.L., Donovan J.W., Gribben J.G. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 1999, 77:259-265.
25. Moreno C., Villamor N., Esteve J., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563-4569.
26. Farina L., Carniti C., Dodero A., et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009, 94:654-662.
27. Ritgen M., Böttcher S., Stilgenbauer S., et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: Results from the GCLLSG CLL3X trial. Leukemia 2008, 22:1377-1386.
28. Rawstron A.C., Villamor N., Ritgen M., et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21:956-964.
29. Böttcher S., Stilgenbauer S., Busch R., et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy - a comparative analysis. Leukemia 2009, 23:2007-2017.
30. Provan D., Bartlett-Pandite L., Zwicky C., et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228-2235.
31. Donovan J.W., Andersen N.S., Poor C.M., Bowers D., Gribben J.G. Prospective analysis of minimal residual disease detection in patients with CLL undergoing autologous and allogeneic BMT. [abstract]. Blood (ASH Annual Meeting Abstracts) 1998, 652a.
32. Bosch F., Ferrer A., Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14:155-161.
33. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
34. Sayala H.A., Moreton P., Kennedy B., et al. Eradication of minimal residual disease with alemtuzumab in chronic lymphocytic leukemia is associated with prolonged survival and is an appropriate theraputic endpoint for relapsed CLL. [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:916a.
35. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities. Clin Cancer Res 2005, 11:7757-7763.
36. Oelschlaegel U., Bornhäuser M., Kiani A., et al. Flow cytometric detection of minimal residual disease one year post allogeneic stem cell transplantation predicts outcome in patients with B-CLL. Blood (ASH Annual Meeting Abstracts) 2009, 114:88.
37. Pavletic S.Z., Khouri I.F., Haagenson M., et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J Clin Oncol 2005, 23:5788-5794.
38. Michallet M., Sobh M., Milligan D., et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 2010, 24:1725-1731.
39. Dreger P., Brand R., Hansz J., et al. Low treatment-related mortality but retained graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using reduced-intensity conditioning. Leukemia 2003, 17:841-848.
40. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006, 12:1056-1064.
41. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology.(Am.Soc.Hematol Educ.Program.) 2009, 2009:596-603.
42. Toze C.L., Galal A., Barnett M.J., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005, 36:825-830.
43. Drobyski W.R., Hessner M., Klein J.P., et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999, 94:434-441.
44. Hess G., Bunjes D., Siegert W., et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005, 23:7583-7593.
45. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
46. Bargou R., Leo E., Zugmaier G., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
47. Aue G., Njuguna N., Tian X., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.